S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
Log in

Inogen Stock Forecast, Price & News

-1.42 (-3.13 %)
(As of 01/15/2021 12:00 AM ET)
Today's Range
Now: $43.97
50-Day Range
MA: $42.02
52-Week Range
Now: $43.97
Volume233,520 shs
Average Volume168,052 shs
Market Capitalization$972.53 million
P/E RatioN/A
Dividend YieldN/A
Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was founded in 2001 and is headquartered in Goleta, California.
Inogen logo


Overall MarketRank

1.33 out of 5 stars

Medical Sector

525th out of 1,480 stocks

Surgical Appliances & Supplies Industry

16th out of 31 stocks

Analyst Opinion: 2.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Surgical appliances & supplies
Current SymbolNASDAQ:INGN



Sales & Book Value

Annual Sales$361.94 million
Cash Flow$1.63 per share
Book Value$15.67 per share


Net Income$20.95 million


Market Cap$972.53 million
Next Earnings Date2/23/2021 (Estimated)
-1.42 (-3.13 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive INGN News and Ratings via Email

Sign-up to receive the latest news and ratings for INGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Inogen (NASDAQ:INGN) Frequently Asked Questions

How has Inogen's stock been impacted by COVID-19 (Coronavirus)?

Inogen's stock was trading at $40.61 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, INGN stock has increased by 8.3% and is now trading at $43.97.
View which stocks have been most impacted by COVID-19

Is Inogen a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Inogen stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INGN, but not buy additional shares or sell existing shares.
View analyst ratings for Inogen
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Inogen?

Wall Street analysts have given Inogen a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Inogen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Inogen's next earnings date?

Inogen is scheduled to release its next quarterly earnings announcement on Tuesday, February 23rd 2021.
View our earnings forecast for Inogen

How were Inogen's earnings last quarter?

Inogen, Inc. (NASDAQ:INGN) issued its quarterly earnings results on Wednesday, November, 4th. The medical technology company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.02) by $0.06. The medical technology company earned $74.30 million during the quarter, compared to analyst estimates of $76.06 million. Inogen had a negative net margin of 0.66% and a positive return on equity of 0.21%. The firm's revenue for the quarter was down 19.1% compared to the same quarter last year. During the same quarter last year, the company earned $0.31 earnings per share.
View Inogen's earnings history

What price target have analysts set for INGN?

5 analysts have issued 1 year price objectives for Inogen's stock. Their forecasts range from $35.00 to $75.00. On average, they anticipate Inogen's share price to reach $53.75 in the next twelve months. This suggests a possible upside of 22.2% from the stock's current price.
View analysts' price targets for Inogen
or view Wall Street analyst' top-rated stocks.

Who are some of Inogen's key competitors?

What other stocks do shareholders of Inogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), (MDVN) (MDVN), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), First Solar (FSLR), Intel (INTC) and Netflix (NFLX).

Who are Inogen's key executives?

Inogen's management team includes the following people:
  • Mr. Scott Wilkinson, CEO, Pres & Director (Age 56, Pay $520.62k)
  • Mr. Brenton Taylor, Co-founder & Exec. VP of Engineering (Age 40, Pay $325.88k)
  • Ms. Alison Perry Bauerlein, Co-founder, Exec. VP of Fin., CFO, Corp. Sec. & Corp. Treasurer (Age 40, Pay $371.06k)
  • Mr. Byron Myers, Founder & Exec. VP of Marketing (Age 42, Pay $356.95k)
  • Mr. Bart Sanford, Exec. VP of Operations (Age 55, Pay $372.87k)
  • Mr. Matthew James Bacso C.F.A., CFA, Investor Relations & Corp. Devel. Mang.
  • Mr. Arron Retterer, Exec. VP of Sales
  • Mr. Matthew Pigeon, Investor Relations Officer

What is Inogen's stock symbol?

Inogen trades on the NASDAQ under the ticker symbol "INGN."

Who are Inogen's major shareholders?

Inogen's stock is owned by many different retail and institutional investors. Top institutional investors include State of Alaska Department of Revenue (0.06%) and 6 Meridian (0.02%). Company insiders that own Inogen stock include Alison Bauerlein, Brenton Taylor, Heath Lukatch and Loren L Mcfarland.
View institutional ownership trends for Inogen

Which major investors are selling Inogen stock?

INGN stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have sold Inogen company stock in the last year include Alison Bauerlein, and Brenton Taylor.
View insider buying and selling activity for Inogen
or view top insider-selling stocks.

Which major investors are buying Inogen stock?

INGN stock was acquired by a variety of institutional investors in the last quarter, including 6 Meridian. Company insiders that have bought Inogen stock in the last two years include Heath Lukatch, and Loren L Mcfarland.
View insider buying and selling activity for Inogen
or or view top insider-buying stocks.

How do I buy shares of Inogen?

Shares of INGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Inogen's stock price today?

One share of INGN stock can currently be purchased for approximately $43.97.

How big of a company is Inogen?

Inogen has a market capitalization of $972.53 million and generates $361.94 million in revenue each year. The medical technology company earns $20.95 million in net income (profit) each year or $1.07 on an earnings per share basis. Inogen employs 1,020 workers across the globe.

What is Inogen's official website?

The official website for Inogen is www.inogen.com.

How can I contact Inogen?

Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The medical technology company can be reached via phone at 805-562-0500 or via email at [email protected]

This page was last updated on 1/16/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.